Interleukin-2 liposomal

Drug Profile

Interleukin-2 liposomal

Alternative Names: IL-2 liposomal; Interleukin-2-liposomal - OncoTherapeutics; L-IL-2; Liposomal interleukin-2; Liposomal-IL-2; Liposome-encapsulated IL-2; Liposome-encapsulated interleukin-2; OncoLipin 2; OTx 287

Latest Information Update: 06 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Minnesota
  • Developer Biomira USA; Oncodigm BioPharma
  • Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
  • Mechanism of Action Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Feb 2017 Discontinued - Phase-II for Cancer in USA (Inhalation)
  • 22 Jul 2005 Interleukin-2 liposomal is available for licensing outside of North America (
  • 24 May 2004 Oncodigm BioPharma is developing liposomal interleukin-2
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top